IgA Nephropathy News and Research

RSS
IgA nephropathy (IgAN), also known as Berger’s disease, is the leading cause of primary glomerulonephritis all over the world. It is autoimmune in origin, characterized by the stimulation of genetically determined formation of concentration of IgA1 with galactose-deficient O-glycans in the hinge-region (Hit 1) in the blood. These stimulate anti-glycan antibody production, followed by binding with the aberrantly glycated IgA1.
Repurposed drug for acute lung injury in COVID-19

Repurposed drug for acute lung injury in COVID-19

Low socioeconomic status associated with certain kidney diseases

Low socioeconomic status associated with certain kidney diseases

UAB researchers find key role for IgG autoantibodies in IgA nephropathy

UAB researchers find key role for IgG autoantibodies in IgA nephropathy

Omeros’ OMS721 receives positive opinion from EMA's COMP for treating hematopoietic stem cell transplant

Omeros’ OMS721 receives positive opinion from EMA's COMP for treating hematopoietic stem cell transplant

Worldwide study to examine new treatments for IgA nephropathy

Worldwide study to examine new treatments for IgA nephropathy

Omeros’ OMS721 receives orphan drug designation from FDA for treatment of IgA nephropathy

Omeros’ OMS721 receives orphan drug designation from FDA for treatment of IgA nephropathy

Scientists identify genetic clues to chronic kidney disease

Scientists identify genetic clues to chronic kidney disease

Researchers uncover new genetic clues linked to autoimmune kidney disease

Researchers uncover new genetic clues linked to autoimmune kidney disease

Researchers discover strong genetic risk factor for IgA nephropathy

Researchers discover strong genetic risk factor for IgA nephropathy

Study links alpha-defensin genes to IgA nephropathy risk

Study links alpha-defensin genes to IgA nephropathy risk

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Pharmalink AB acquires anti-inflammatory drug candidate from Synartro AB

Pharmalink AB acquires anti-inflammatory drug candidate from Synartro AB

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Pharmalink's Busulipo receives FDA orphan drug designation

Pharmalink's Busulipo receives FDA orphan drug designation

Pharmalink commences Nefecon Phase IIb study in primary IgA nephropathy

Pharmalink commences Nefecon Phase IIb study in primary IgA nephropathy

Absence of proteinuria good prognostic sign in IgA nephropathy

Absence of proteinuria good prognostic sign in IgA nephropathy

Long-term prognosis excellent for patients with IgA nephropathy

Long-term prognosis excellent for patients with IgA nephropathy